Drug Profile
SB 01 - Spine Biopharma
Alternative Names: P2K; Peniel 2K; Peniel-2000; Remedisc; SB-01; YH-14618Latest Information Update: 22 Jul 2022
Price :
$50
*
At a glance
- Originator Ensol Biosciences
- Developer Spine Biopharma; Yuhan
- Class
- Mechanism of Action Nerve growth factor inhibitors; Transforming growth factor beta receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Intervertebral disc degeneration
Most Recent Events
- 22 Jul 2022 No development reported - Phase-II for Intervertebral disc degeneration in South Korea (Intra-articular)
- 11 May 2022 Phase-III clinical trials in Intervertebral disc degeneration in USA (Intra-articular)
- 11 May 2022 The US FDA grants Study May Proceed Letter for SB 01 in Intervertebral disc degeneration